MA35061B1 - Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase - Google Patents

Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Info

Publication number
MA35061B1
MA35061B1 MA36357A MA36357A MA35061B1 MA 35061 B1 MA35061 B1 MA 35061B1 MA 36357 A MA36357 A MA 36357A MA 36357 A MA36357 A MA 36357A MA 35061 B1 MA35061 B1 MA 35061B1
Authority
MA
Morocco
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
derivatives
carboxylase inhibitors
Prior art date
Application number
MA36357A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA35061B1 publication Critical patent/MA35061B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE FORMULE (I) OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE FORMULE G REPRÉSENTE (II) OU (III) ET R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION ; SUR DES COMPOSITIONS PHARMACEUTIQUES DE CELUI-CI ; ET SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES, D'AFFECTIONS OU DE TROUBLES MODULÉS PAR L'INHIBITION D'UNE OU PLUSIEURS ENZYMES ACÉTYL-COA CARBOXYLASES CHEZ UN ANIMAL.
MA36357A 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase MA35061B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
MA35061B1 true MA35061B1 (fr) 2014-04-03

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36357A MA35061B1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Country Status (41)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN103492388A (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3283A (en) * 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
CA2903431C (fr) 2013-03-14 2022-12-06 Kalyra Pharmaceuticals, Inc. Composes analgesiques bicyclopentanes
EP2994139B1 (fr) 2013-05-10 2019-04-10 Gilead Apollo, LLC Inhibiteurs de l'acc et leurs utilisations
WO2014182951A1 (fr) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Inhibiteurs de l'acc et utilisations associées
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
CN105530940A (zh) * 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
EP3670496A3 (fr) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Inhibiteurs de acc2
CN105814013A (zh) * 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US10457502B2 (en) 2014-05-22 2019-10-29 Symbotic Canada Ulc Tool and method for layer depalletizing
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
US11058703B2 (en) * 2015-12-31 2021-07-13 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
WO2018213140A1 (fr) 2017-05-15 2018-11-22 Zeno Royalties & Milestones, LLC Composés analgésiques
CA3082867C (fr) * 2017-11-21 2022-05-10 Pfizer Inc. Sel de 2-amino-2-(hydroxymethyl)propane-1,3-diol cristallin de l'acide 4-(4-(1 -isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1 '-car bonyl)-6-methoxypyridin-2 -yl)benzoique
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
WO2024140923A1 (fr) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Inhibiteur de prmt5-mta

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
EP1383501B1 (fr) 2001-02-28 2007-04-04 Merck & Co., Inc. Derives de piperidine acyles utilises comme agonistes du recepteur de la melanocortin-4
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7410976B2 (en) 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
CA2617042A1 (fr) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Compose spiro-cyclique
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CA2641766A1 (fr) 2006-02-15 2007-08-23 Abbott Laboratories Nouveaux inhibiteurs d'acetyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabete, de l'obesite et du syndrome metabolique
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
JP2010511035A (ja) 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク スピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008102749A1 (ja) * 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (fr) 2008-05-28 2011-03-23 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
CA2729412A1 (fr) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Nouveaux acides spirochromanone carboxyliques
EP2310015A4 (fr) 2008-07-14 2011-10-26 Cropsolution Inc Modulateurs de l acétyl-coenzyme a carboxylase et procédés d utilisation associés
CA2729581A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Heteroaryles fluores
EA018492B1 (ru) 2008-08-28 2013-08-30 Пфайзер Инк. Диоксабицикло[3.2.1]октан-2,3,4-триольные производные
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
EP2406253B1 (fr) 2009-03-11 2013-07-03 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
CA2754523A1 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
EP2499140A1 (fr) * 2009-11-10 2012-09-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
AP3283A (en) 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2811033C (fr) * 2010-09-30 2015-10-20 Pfizer Inc. Inhibiteurs de n1-pyrazolospirocetone acetyl-coa carboxylase

Also Published As

Publication number Publication date
EP2699576A1 (fr) 2014-02-26
SG194142A1 (en) 2013-11-29
NZ616156A (en) 2014-08-29
UA107753C2 (xx) 2015-02-10
KR20140015511A (ko) 2014-02-06
IL228949A (en) 2016-11-30
MX348860B (es) 2017-06-30
US8802688B2 (en) 2014-08-12
US20120270893A1 (en) 2012-10-25
US20150336958A1 (en) 2015-11-26
MX2013012313A (es) 2014-01-31
KR101567659B1 (ko) 2015-11-09
PL2699576T3 (pl) 2016-05-31
TWI464171B (zh) 2014-12-11
GT201300258A (es) 2015-06-02
TN2013000393A1 (fr) 2015-01-20
CN106117205B (zh) 2018-09-21
AU2012245996B2 (en) 2016-09-01
TW201305162A (zh) 2013-02-01
HRP20151397T1 (hr) 2016-01-15
UY34027A (es) 2013-04-05
JP5657174B2 (ja) 2015-01-21
WO2012143813A1 (fr) 2012-10-26
MY162167A (en) 2017-05-31
US20150112068A1 (en) 2015-04-23
CO6801757A2 (es) 2013-11-29
CN106117205A (zh) 2016-11-16
AP3499A (en) 2015-12-31
CY1117122T1 (el) 2017-04-05
GEP20166474B (en) 2016-05-10
EA201391288A1 (ru) 2014-04-30
AU2012245996A1 (en) 2013-10-03
PE20141187A1 (es) 2014-09-18
HUE028602T2 (hu) 2016-12-28
CR20130464A (es) 2013-10-16
US20140323730A1 (en) 2014-10-30
PT2699576E (pt) 2016-03-09
DK2699576T3 (en) 2016-02-15
RS54526B1 (en) 2016-06-30
EP2699576B1 (fr) 2015-12-09
SI2699576T1 (sl) 2016-02-29
ECSP13013038A (es) 2014-01-31
CU24164B1 (es) 2016-03-31
JP2014515755A (ja) 2014-07-03
ES2561452T3 (es) 2016-02-26
CN103492388A (zh) 2014-01-01
NI201300111A (es) 2014-02-12
CA2831380A1 (fr) 2012-10-26
DOP2013000243A (es) 2013-12-31
IL228949A0 (en) 2013-12-31
ME02312B (me) 2016-06-20
AR086198A1 (es) 2013-11-27
EA022375B1 (ru) 2015-12-30
CA2831380C (fr) 2016-04-05
AP2013007129A0 (en) 2013-09-30
CL2013002794A1 (es) 2013-12-27
CU20130126A7 (es) 2014-01-29

Similar Documents

Publication Publication Date Title
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA46342B1 (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations
EA201170150A1 (ru) Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона